<DOC>
	<DOCNO>NCT00274794</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , busulfan , etoposide , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving colony-stimulating factor , G-CSF , monoclonal antibody , rituximab , chemotherapy , etoposide , help stem cell move bone marrow blood collect store transplant . Giving etoposide G-CSF together rituximab peripheral stem cell transplant may effective treatment non-Hodgkin 's lymphoma . PURPOSE : This randomized clinical trial study well give etoposide G-CSF without rituximab work treat patient undergo autologous peripheral stem cell transplant B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>VP G-CSF With Without Rituximab Autologous Peripheral Stem Cell Transplant For NHL</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether mobilization etoposide filgrastim ( G-CSF ) without rituximab influence CD34+ cell yield patient undergo autologous peripheral blood stem cell transplantation B-cell non-Hodgkin 's lymphoma . - Determine acute toxicity rituximab combination etoposide G-CSF peripheral blood stem cell mobilization patient . OUTLINE : This randomize study . - Stem cell mobilization : Patients randomize 1 2 mobilization arm . - Arm I : Patients receive rituximab IV 4 hour day 1 , 8 , 15 . Patients also receive etoposide IV 4 hour day 15 filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 17 continue approximately day 25 . Patients undergo apheresis 5 day adequate amount stem cell collect . After stem cell collection complete , patient proceed preparative regimen . - Arm II : Patients receive etoposide IV 4 hour day 1 G-CSF SC begin day 3 continue approximately day 11 . Patients undergo apheresis 5 day adequate amount stem cell collect . After stem cell collection complete , patient proceed preparative regimen . - Preparative regimen : Patients receive oral busulfan daily day -8 -4 , etoposide IV 4 hour day -4 , cyclophosphamide IV 2 hour day -3 -2 . - Autologous peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo autologous PBSCT day 0 . Beginning day 5 , patient receive G-CSF SC IV daily blood count recover . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients Bcell malignancy appropriate candidate highdose chemotherapy autologous stem cell transplantation meet 1 follow criterion : Relapsed refractory Bcell nonHodgkin 's Lymphoma ( NHL ) Patients Bcell NHL first remission significant risk later relapse Patients Bcell malignancy otherwise eligible autologous stem cell transplantation PATIENT CHARACTERISTICS : Life expectancy least 2 month Cardiac ejection fraction ≥ 45 % DLCO ≥ 45 % Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 2.0 mg/dL AST &lt; 2 time normal Platelet count ≥ 50,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Absolute lymphocyte count ≤ 10,000/mm^3 HIV negative No severe medical psychiatric illnesses Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : More 8 week since prior rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>